Eliem Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.89 Insider Own0.70% Shs Outstand26.24M Perf Week-10.82%
Market Cap81.14M Forward P/E- EPS next Y-1.82 Insider Trans0.00% Shs Float17.75M Perf Month0.00%
Income-45.50M PEG- EPS next Q-0.41 Inst Own66.00% Short Float4.26% Perf Quarter-58.61%
Sales- P/S- EPS this Y-368.80% Inst Trans0.81% Short Ratio3.43 Perf Half Y-66.92%
Book/sh5.91 P/B0.59 EPS next Y-11.80% ROA-29.10% Target Price24.00 Perf Year-
Cash/sh5.28 P/C0.65 EPS next 5Y- ROE-40.70% 52W Range2.52 - 29.69 Perf YTD-66.92%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-88.51% Beta-
Dividend %- Quick Ratio19.30 Sales past 5Y- Gross Margin- 52W Low35.32% ATR0.55
Employees37 Current Ratio19.30 Sales Q/Q- Oper. Margin- RSI (14)44.15 Volatility15.41% 15.85%
OptionableNo Debt/Eq0.00 EPS Q/Q35.20% Profit Margin- Rel Volume0.02 Prev Close3.46
ShortableYes LT Debt/Eq0.00 EarningsMay 16 BMO Payout- Avg Volume220.19K Price3.41
Recom1.70 SMA20-14.28% SMA50-8.47% SMA200-65.90% Volume3,019 Change-1.45%
Jun-27-22 04:01PM  
May-16-22 06:10AM  
May-10-22 10:45AM  
May-09-22 09:55AM  
Apr-25-22 07:00AM  
Apr-05-22 07:00AM  
Mar-21-22 07:00AM  
Mar-07-22 04:10PM  
Feb-11-22 07:00AM  
Feb-07-22 07:00AM  
Jan-18-22 07:00AM  
Nov-25-21 07:35AM  
Nov-08-21 04:01PM  
Nov-04-21 07:00AM  
Oct-04-21 10:54AM  
Sep-13-21 04:10PM  
Aug-16-21 10:22AM  
Aug-12-21 09:06PM  
Aug-09-21 10:33PM  
Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its two lead drug candidates are ETX-810 for chronic pain, which is in Phase IIa clinical trial; and ETX-155 for the treatment of major depressive disorder, perimenopausal depression, and focal onset seizures that is in Phase I clinical trial. The company also develops preclinical pipeline programs, such as Kv7 Program for pain, epilepsy, and depression; and Anxiolytic for the treatment of generalized anxiety disorder. Eliem Therapeutics, Inc. was incorporated in 2018 and is headquartered in Redmond, Washington.